Methotrexate (MTX) therapy for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams34942
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program.
Halifax, NS:
Nova Scotia Health Authority
, 2024.
- Pamphlet Number
- 1138
- Available Online
- View Pamphlet
Methotrexate (MTX) may help you manage your over-active immune response caused by your inflammatory bowel disease (IBD). This pamphlet gives information about what MTX is, combination therapy in IBD, who should not take MTX, how MTX is given, and possible side effects, and what you can do to lower the chance of side effects.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Alternate Title
- Methotrexate (MTX) therapy for IBD
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2024
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (13 p.) : digital, PDF file
- Subjects (MeSH)
- Methotrexate
- Inflammatory Bowel Diseases
- Immunosuppressive Agents
- Subjects (LCSH)
- Methotrexate
- Immunosuppressive agents
- Inflammatory bowel diseases
- Specialty
- Medications
- Abstract
- Methotrexate (MTX) may help you manage your over-active immune response caused by your inflammatory bowel disease (IBD). This pamphlet gives information about what MTX is, combination therapy in IBD, who should not take MTX, how MTX is given, and possible side effects, and what you can do to lower the chance of side effects.
- Responsibility
- Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Pamphlet Number
- 1138
Corticosteroid therapy for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams35480
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program.
Halifax, NS:
Nova Scotia Health Authority
, 2024.
- Pamphlet Number
- 1546
- Available Online
- View Pamphlet
A corticosteroid medication may help you manage your inflammatory bowel disease (IBD). This pamphlet explains what corticosteroids are, how well they work, and how they are given. Information about precautions, possible side effects, and what to expect after your treatment is included.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Alternate Title
- Corticosteroid therapy for IBD
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2024
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (10 p.) : digital, PDF file
- Subjects (MeSH)
- Inflammatory Bowel Diseases - drug therapy
- Prednisone
- Subjects (LCSH)
- Inflammatory bowel diseases
- Prednisone
- Specialty
- Medications
- Abstract
- A corticosteroid medication may help you manage your inflammatory bowel disease (IBD). This pamphlet explains what corticosteroids are, how well they work, and how they are given. Information about precautions, possible side effects, and what to expect after your treatment is included.
- Notes
- This pamphlet replaced pamphlet 1139: Prednisone Therapy
- Previous title: Corticosteroid therapy in inflammatory bowel disease (IBD)
- Responsibility
- Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Pamphlet Number
- 1546
Azathioprine or mercaptopurine therapy for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams35565
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program.
Halifax, NS:
Nova Scotia Health Authority
, 2024.
- Pamphlet Number
- 1079
- Available Online
- View Pamphlet
Azathioprine (Imuran®) or mercaptopurine may help you manage your over-active immune response caused by your inflammatory bowel disease (IBD). This pamphlet gives information about combination therapy in IBD, possible side effects of these medications, and what you can do to lower the chance of side effects.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Alternate Title
- Azathioprine or mercaptopurine therapy for IBD
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2024
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (6 p.): digital, PDF file
- Subjects (MeSH)
- Immunosuppressive Agents
- Azathioprine
- Mercaptopurine
- Subjects (LCSH)
- Immunosuppressive agents
- Specialty
- Medications
- Abstract
- Azathioprine (Imuran®) or mercaptopurine may help you manage your over-active immune response caused by your inflammatory bowel disease (IBD). This pamphlet gives information about combination therapy in IBD, possible side effects of these medications, and what you can do to lower the chance of side effects.
- Notes
- Previous title: Azathioprine (Imuran) therapy
- Previous title: Azathioprine and mercaptopurine therapy
- Responsibility
- Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Pamphlet Number
- 1079
Risankizumab (Skyrizi®) therapy for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams38191
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program.
Halifax, NS:
Nova Scotia Health Authority
, 2023.
- Pamphlet Number
- 2345
- Available Online
- View Pamphlet
Risankizumab is a biologic medication. A biologic medication is a type of medication that treats inflammation. This pamphlet explains how risankizumab works, how it is given, and how long you can expect to take it. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Alternate Title
- Risankizumab (Skyrizi®) therapy for IBD
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2023
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (9 p.) : digital, PDF file
- Subjects (MeSH)
- Inflammatory Bowel Diseases - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Specialty
- Gastrointestinal System
- Medications
- Abstract
- Risankizumab is a biologic medication. A biologic medication is a type of medication that treats inflammation. This pamphlet explains how risankizumab works, how it is given, and how long you can expect to take it. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 2345
